Basic CSF parameters and MRZ reaction help in differentiating MOG antibody-associated autoimmune disease versus multiple sclerosis
Principal Investigators | Benjamin Vlad,Ina Reichen,Stephan Neidhart,Marc Hilty, Dimitra Lekaditi,Christine Heuer, Amanda Eisele, Mario Ziegler, Markus Reindl, Andreas Lutterotti, Axel Regeniter and Ilijas Jelcic
Institution | University Hospital Zurich (Switzerland), University of Zurich (Switzerland), Medizinische Universität Innsbruck (Austria), Neurozentrum Bellevue (Switzerland), and medica Medizinische Laboratorien Dr. F. Kaeppeli (Switzerland)
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this collection by fully or partially covering the article processing charge.
Delimiting MOGAD as a disease entity using translational imaging
Principal Investigators | Frederike C. Oertel, Maria Hastermann, and Friedemann Paul
Institution | Charité – Universitätsmedizin Berlin (Germany)
Aim | This article reviews suitable animal models for translational MOGAD research and the current state and prospect of translational imaging in MOGAD.
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this collection by fully or partially covering the article processing charge.
Epidemiology of MOGAD: A review of prevalence and incidence worldwide
Principal Investigators | Jyh Yung Hor and Kazuo Fujihara
Institution | Penang General Hospital (Malaysia), Fukushima Medical University (Japan) and Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience (Japan)
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this collection by fully or partially covering the article processing charge.
Helicobacter pylori infection may influence prevalence and disease course in MOGAD similar to MS but not AQP4-IgG associated NMOSD
Principal Investigators | Chaithra Malli, Lekha Pandit, Anita D’Cunha and Akshatha Sudhir
Institution | Nitte University (India)
Aim | To evaluate frequency of Hp IgG among patients with MOGAD, MS, NMOSD and matched controls and its effect on disease course. To ascertain whether childhood socio economic factors were linked to prevalence of Hp infection.
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this important collection by fully or partially covering the article processing charge.
High level of agreement in a fixed vs live cell-based assay for antibodies to MOG in a real-world clinical laboratory setting
Principal Investigators | Tammy L. Smith, Thomas R. Haven, Lauren M. Zuromski, Kyphuong Luong, Stacey L. Clardy and Lisa K. Peterson
Institutions | VA Salt Lake City Health Care System, The University of Utah, ARUP Institute for Clinical and Experimental Pathology and George E. Whalen Department of Veterans Affairs Medical Center (USA)
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this important collection by fully or partially covering the article processing charge.
Investigating the association between neoplasms & MOGAD
Principal Investigators | Milena Trentinaglia, Alessandro Dinoto, Sara Carta, Vanessa Chiodega, Sergio Ferrari, Vincenzo Andreone, Giorgia Teresa Maniscalco and Sara Mariotto
Institutions | University of Verona, Neurological Clinic and Stroke Unit – Naples and Multiple Sclerosis Center – Naples (Italy)
Aim | To investigate the occurrence of tumors in a cohort of patients with MOGAD and to describe their clinical features, in addition to previously reported cases.
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this important collection by fully or partially covering the article processing charge.
Institutions | Clínica Alemana de Santiago (Chile) & Hospital Ramos Mejia (Argentina)
Aim | To develop a consensus on the use of disease-modifying treatments in NMOSD patients and write guidelines for Latin America of treatment for NMOSD (aquaporin-4 positive and negative patients).
Pathology of MOGAD: A comparison with MS and AQP4+ NMOSD
Principal Investigators | Yoshiki Takai, Tatsuro Misu, Kazuo Fujihara and Masashi Aoki
Institution | Tohoku University and Fukushima Medical University (Japan)
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this collection by fully or partially covering the article processing charge.
Principal Investigators | Osman Corbali, MD and Tanuja Chitnis, MD
Institution | Brigham and Women’s Hospital (USA)
Aim | Overview of myelin oligodendrocyte glycoprotein antibody disease
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this important collection by fully or partially covering the article processing charge.
Pediatric MOGAD in southern China: analysis of 93 cases
Principal Investigators | Xiaojing Li, Wenlin Wu, Chi Hou, Yiru Zeng, Wenxiao Wu, Lianfeng Chen, Yinting Liao, Haixia Zhu, Yang Tian, Bingwei Peng, Kelu Zheng, Kaili Shi, Ying Li, Yuanyuan Gao, Yani Zhang, Haisheng Lin and Wen-Xiong Chen
Institution | Guangzhou Medical University, Guangzhou (China)
Aim | To study the clinical features of children diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in southern China.
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this important collection by fully or partially covering the article processing charge.
Retinal structural and microvascular changes in MOGAD & NMOSD: An OCT/OCTA study
Principal Investigators | Yanlin Lang, William Robert Kwapong, Lingyao Kong, Ziyan Shi, Xiaofei Wang, Qin Du, Bo Wu, Hongyu Zhou
Institution | West China Hospital, Sichuan University (China)
Aim | To compare the optical coherence tomography (OCT)/OCT angiography (OCTA) measures in patients with neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD).
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this important collection by fully or partially covering the article processing charge.
Principal Investigators | Elena Grebenciucova, Gina S. Perez Giraldo and Natalia Gonzalez Caldito
Institution | Northwestern University (USA)
Aim | To empower physicians to recognize diagnostic challenges of transverse myelitis associated with MOGAD, such as low predictive value of low titers of MOG antibodies for the diagnosis of MOGAD, importance of both clinical and radiological characteristics, exclusion of other causes, discussing risk of recurrence, and administering acute treatment as well as communicating the rationale of whether chronic treatments are necessary to reduce the risk of relapse after the first relapse.
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this important collection by fully or partially covering the article processing charge.
Two case reports and systematic review of the literature of adult cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibody
Principal Investigators | Xu M. Hui, Ma Chi, Ming Dong, Liu Yue and Wang Xu
Institution | The First Hospital of Jilin University (China)
Aim | To further characterize the clinical symptoms, magnetic resonance imaging (MRI) findings, and prognosis of CCE with anti-MOG antibody.
Funds Awarded | TSF has provided $35,000 to assist authors contributing to this collection by fully or partially covering the article processing charge.
Aim I | Determine the frequency of misdiagnosis of NMOSD patients as MS, and the point prevalence of misdiagnosis in different geographic census regions
Aim II | Identify the frequency of utilization of FDA-approved MS therapies in misdiagnosed NMOSD patients
Aim III | Understand the cost of misdiagnosis of NMOSD patients
Institution | Charité – Universitätsmedizin Berlin (Germany)
Aim I | To investigate the involvement of inflammasome in NMOSD, by detecting pyroptosis and the inflammasome effector cytokine IL1β in microglia-mediated astrocytic damage by AQP4-IgG
Aim II | To study whether inhibition of inflammasome and its effectors may protect astrocytes from inflammasome-mediated damage
Aim | To better understand the interplay of genetics, metabolics, and other non-genetic factors that relate to NMOSD/MOGAD patient outcomes, including quality of life.
Aim I | To compare retinal vascular plexus densities between eyes with a history of optic neuritis from people with NMOSD, MOGAD, MS and controls
Aim II | To compare retinal vascular plexus densities between eyes without a history of optic neuritis from patients with NMOSD, MOGAD, MS and controls
Aim III | To assess correlations of retinal vascular plexus densities with visual function in NMOSD, MOGAD and MS eyes
Aim | To depict the impact of neuromyelitis optica spectrum disorder (NMOSD) on employment, job loss, and work hours in a multi-country prospective survey-based study of people living with NMOSD
Aim I | Develop longitudinal database and biorepository for MOG Antibody Disease (MOGAD) patients at the Stanford Neuroimmunology Center, including multi-center collaboration. Demographic, clinical outcomes, biochemical (including MOG-IgG serial titers, presence of co-neuronal antibodies), neuroimaging and neuropsychological outcomes, when available.
Aim II | To determine if MOG IgG positivity or titer predicts index event severity or relapse
Aim III | To correlate MOG IgG serostatus with serum and cerebrospinal fluid (CSF) immune profiles (pleocytosis, oligoclonal bands, paired serum/CSF IL-6, TNF-alpha, T and B lymphocyte profiles) to inform immunopathogenesis and treatment
Aim | The overall goals of this study are to better understand the effects of the SARS-CoV-2 pandemic and COVID-19 in our population of patients with NMOSD.
Aim I | To describe the epidemiologic characteristics of all patients who carry a diagnosis of NMOSD within the Department of Defense/Defense Medical Surveillance System (DMSS).
Aim II | To confirm the presence of Aquaporin-4 and MOG autoantibodies in pre-symptomatic NMO samples.
Aim | To pilot a novel point-of-care dry blood spot diagnostic test for patients with aquaporin 4-antibody (AQP4) seropositive neuromyelitis optica spectrum disorder (NMOSD).
Aim | To evaluate the effect of different disease modifying treatments on attack and disability prevention in children with neuromyelitis optica spectrum disorder.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By continuing to use our website, you consent to the use of all the cookies. Read our privacy policy here.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
WARNING: Internet Explorer does not support modern web standards. This site may not function
correctly on this browser and is best viewed on
Chrome,
Firefox
or Edge
browsers.
Learn More.
